Health Catalyst (NASDAQ:HCAT) Given “Overweight” Rating at Piper Sandler

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating reissued by investment analysts at Piper Sandler in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock, up from their prior price target of $11.00. Piper Sandler’s price target would indicate a potential upside of 40.85% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Citigroup raised their target price on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. JPMorgan Chase & Co. upped their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Royal Bank of Canada raised their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Finally, Stephens lifted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Stock Up 4.8 %

NASDAQ HCAT opened at $8.52 on Tuesday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The business has a 50 day moving average price of $8.13 and a two-hundred day moving average price of $7.28. The stock has a market cap of $518.44 million, a PE ratio of -6.31 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter last year, the company posted ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, sell-side analysts predict that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at $998,613. This represents a 3.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock worth $257,555 over the last 90 days. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. Price T Rowe Associates Inc. MD boosted its position in shares of Health Catalyst by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after buying an additional 2,831 shares during the period. SG Americas Securities LLC acquired a new position in Health Catalyst during the 2nd quarter worth $187,000. Nepsis Inc. grew its stake in shares of Health Catalyst by 8.3% in the second quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after purchasing an additional 95,686 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Finally, Perfromance Wealth Partners LLC acquired a new position in shares of Health Catalyst during the second quarter valued at $64,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.